Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Dancey · SciRah

Researcher profile · Semantic Scholar

J. Dancey

Share profile

J. Dancey — researcher profile on SciRah

h-index: 79
Works: 274
Citations: 52K

Most-cited papers

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
L. Seymour, J. Bogaerts, A. Perrone, R. Ford +14 more
2017The Lancet Oncology2,125 citations Open access
Semantic Scholar
RECIST 1.1 – Update and Clarification: From the RECIST Committee
Lawrence H. Schwartz, S. Litière, E. D. de Vries, R. Ford +15 more
2016European Journal of Cancer1,839 citations Open access
Semantic Scholar
Response assessment criteria for brain metastases: proposal from the RANO group.
Nancy U. Lin, E. Lee, H. Aoyama, I. Barani +22 more
2015The Lancet Oncology939 citations
Semantic Scholar
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
K. Saini, S. Loi, E. de Azambuja, O. Metzger-Filho +4 more
2013Cancer Treatment Reviews366 citations Open access
Semantic Scholar
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz, L. Seymour, S. Litière, R. Ford +15 more
2016European Journal of Cancer352 citations Open access
Semantic Scholar
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
A. Oza, L. Elit, M. Tsao, S. Kamel-Reid +12 more
2011Journal of Clinical Oncology333 citations Open access
Semantic Scholar
The genetic basis for cancer treatment decisions.
J. Dancey, P. Bedard, N. Onetto, T. Hudson
2012Cell328 citations Open access
Semantic Scholar
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
N. Busaidy, A. Farooki, A. Dowlati, J. Perentesis +4 more
2012Journal of Clinical Oncology215 citations Open access
Semantic Scholar
Cancer genomics: technology, discovery, and translation.
B. Tran, J. Dancey, S. Kamel-Reid, J. Mcpherson +9 more
2012Journal of Clinical Oncology189 citations Open access
Semantic Scholar
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
M. Lacouture, M. Maitland, S. Segaert, A. Setser +16 more
2010Supportive Care in Cancer159 citations
Semantic Scholar
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
P. Wen, Susan M. Chang, K. Lamborn, J. Kuhn +16 more
2014Neuro-Oncology152 citations Open access
Semantic Scholar
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
N. Lin, J. Wefel, E. Lee, D. Schiff +18 more
2013The Lancet Oncology140 citations
Semantic Scholar
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
Nancy U. Lin, E. Lee, H. Aoyama, Igor J. Barani +21 more
2013The Lancet Oncology124 citations
Semantic Scholar
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
E. Lee, J. Kuhn, K. Lamborn, L. Abrey +15 more
2012Neuro-Oncology121 citations Open access
Semantic Scholar
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
J. D. De Souza, D. Davis, Yu-Jian Zhang, A. Khattri +13 more
2012Clinical Cancer Research113 citations Open access
Semantic Scholar
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Cynthia X. Ma, M. Ellis, G. Petroni, Zhan-Fang Guo +18 more
2012Breast Cancer Research and Treatment111 citations Open access
Semantic Scholar
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care
F. Miller, R. Hayeems, J. Bytautas, Philippe Bédard +9 more
2013European Journal of Human Genetics104 citations Open access
Semantic Scholar
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials
D. Ediebah, C. Quinten, C. Coens, J. Ringash +12 more
2018Cancer98 citations Open access
Semantic Scholar
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
D. Camidge, Eudocia Q. Lee, Nancy U. Lin, K. Margolin +15 more
2018The Lancet Oncology94 citations
Semantic Scholar
Conducting clinical trials—costs, impacts, and the value of clinical trials networks: A scoping review
C. Bentley, S. Cressman, K. van der Hoek, K. Arts +2 more
2019Clinical Trials88 citations Open access
Semantic Scholar
Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial
B. Tran, Andrew M. K. Brown, Philippe Bédard, E. Winquist +20 more
2013International Journal of Cancer84 citations Open access
Semantic Scholar
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
S. Litière, Gaëlle Isaac, E. D. de Vries, J. Bogaerts +13 more
2019Journal of Clinical Oncology67 citations Open access
Semantic Scholar
Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
D. Schiff, K. Jaeckle, S. Anderson, E. Galanis +11 more
2018Cancer55 citations Open access
Semantic Scholar
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma
M. Davies, P. Fox, N. Papadopoulos, A. Bedikian +16 more
2012Clinical Cancer Research54 citations Open access
Semantic Scholar
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
J. Raizer, L. Abrey, A. Lassman, Susan M. Chang +14 more
2010Neuro-Oncology54 citations Open access
Semantic Scholar
CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada
Stephen Sundquist, G. Batist, K. Brodeur-Robb, Karen G. Dyck +8 more
2021Current Oncology41 citations Open access
Semantic Scholar
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
N. Leighl, S. Laurie, G. Goss, B. Hughes +17 more
2021Journal of Thoracic Oncology35 citations Open access
Semantic Scholar
Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
J. Dancey, J. Monzon
2011Future Oncology31 citations
Semantic Scholar
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
P. Nghiemphu, V. Ebiana, P. Wen, M. Gilbert +15 more
2017Journal of Neuro-Oncology28 citations Open access
Semantic Scholar
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Huanwen Chen, J. Kuhn, K. Lamborn, L. Abrey +15 more
2020Neuro-Oncology Advances24 citations Open access
Semantic Scholar
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
N. Leighl, S. Laurie, G. Goss, B. Hughes +15 more
202024 citations
Semantic Scholar
Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.
T. Skamene, L. Siu, D. Renouf, J. Laskin +10 more
201822 citations
Semantic Scholar
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.
D. Jonker, S. Hotte, A. Razak, D. Renouf +15 more
201721 citations
Semantic Scholar
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
J. Monzon, A. Hay, Gail T. McDonald, J. Pater +4 more
2015European Journal of Cancer21 citations
Semantic Scholar
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
E. Kraut, C. Rhoades, Yilong Zhang, Hao Cheng +8 more
2010Cancer Chemotherapy and Pharmacology20 citations Open access
Semantic Scholar
Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
K. Kim, M. Davies, N. Papadopoulos, A. Bedikian +6 more
2016Journal of Clinical Oncology18 citations
Semantic Scholar
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
K. Saini, B. de las Heras, R. Plummer, V. Moreno +23 more
2020JCO Global Oncology17 citations Open access
Semantic Scholar
Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).
T. Petrella, C. Mihalcioiu, E. Mcwhirter, K. Bélanger +11 more
201316 citations
Semantic Scholar
Targeted therapies and clinical trials in ovarian cancer.
J. Dancey
2013Annals of Oncology16 citations Open access
Semantic Scholar
Targeted agents for the treatment of metastatic melanoma
J. Monzon, J. Dancey
2012OncoTargets and Therapy16 citations Open access
Semantic Scholar
Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator:A Cross-Sectional Analysis
C. Hamm, D. Cavallo-Medved, Devinder Moudgil, Lee McGrath +7 more
2022Cancer Control: Journal of the Moffitt Cancer Cente15 citations Open access
Semantic Scholar
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
R. Goodwin, R. Jamal, D. Tu, W. Walsh +4 more
2013Gynecologic Oncology15 citations
Semantic Scholar
Clinical genomics information management software linking cancer genome sequence and clinical decisions.
Stuart N. Watt, W. Jiao, Andrew M. K. Brown, T. Petrocelli +11 more
2013Genomics15 citations Open access
Semantic Scholar
Management of kidney cancer: canadian kidney cancer forum consensus update 2011.
M. Jewett, A. Finelli, C. Kollmannsberger, L. Wood +64 more
2012Canadian Urological Association journal = Journal de l'Association des urologues du Canada15 citations Open access
Semantic Scholar
Genomics, personalized medicine and cancer practice.
J. Dancey
2012Clinical Biochemistry15 citations
Semantic Scholar
A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.
T. Baetz, Xin-Ni Song, D. Ernst, E. Mcwhirter +13 more
201814 citations
Semantic Scholar
Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
J. Dancey
2012Drugs14 citations
Semantic Scholar
Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials
Georgina Freeman, Jonathan Kimmelman, J. Dancey, J. Monzon
2013British Journal of Cancer12 citations Open access
Semantic Scholar
From quality of publication to quality of care: translating trials to practice.
J. Dancey
2010Journal of the National Cancer Institute11 citations Open access
Semantic Scholar
The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers
Stephen Sundquist, D. Kato, Rebecca Y Xu, James Schoales +2 more
2022Current Oncology10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Mehta×8
Invite
M. Mehta — researcher profile on SciRah
Susan M. Chang×7
Invite
Susan M. Chang — researcher profile on SciRah
F. Hodi×6
Invite
F. Hodi — researcher profile on SciRah
E. D. de Vries×6
Invite
E. D. de Vries — researcher profile on SciRah

×6

Invite

P. Wen — researcher profile on SciRah

Invite

L. Siu — researcher profile on SciRah

Invite

J. Wright — researcher profile on SciRah

Invite

D. Schiff — researcher profile on SciRah

Invite

K. Lamborn — researcher profile on SciRah

Invite

J. Kuhn — researcher profile on SciRah

T. Cloughesy×5

Invite

T. Cloughesy — researcher profile on SciRah

Invite

H. Robins — researcher profile on SciRah